Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

24.17 -0.26 (-1.05%)
Streaming Delayed Price Updated: 1:02 PM EDT, May 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns. 
Via Benzinga
Exposures Product Safety
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Vertex Pharmaceuticals Topples 12% On A Series Of First-Quarter Setbacks
The company paused a study of a cystic fibrosis treatment, right on the heels of a scrapped type 1 diabetes program. 
Via Investor's Business Daily
Topics Government Intellectual Property
Exposures Intellectual Property Political
3 Cash-Heavy Stocks in the Doghouse
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,... 
Via StockStory
Topics Economy
Exposures COVID-19 Supply Chain
Earnings Scheduled For May 1, 2025
Via Benzinga
Preview: Moderna's Earnings
Via Benzinga
What's going on in today's session: S&P500 movers
Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026
Moderna reaffirms 2025 revenue guidance of $1.5 billion–$2.5 billion, cuts 2027 cost forecast by up to $1.7 billion, and targets 2026 approval for its flu/COVID combo shot. 
Via Benzinga
Exposures Product Safety
Thursday's session: gap up and gap down stock in the S&P500 index
Curious about the S&P500 stocks that are gapping on Thursday? Explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
Moderna Reports Q1 Revenue Drop, Warns Of Delay In Covid/Flu Vaccine Approval: Retail Sentiment Sours
The company reported first-quarter revenue of $108 million, down from $167 million in the corresponding period of 2024, and below an analyst estimate of $115.32 million, as per FinChat data. 
Via Stocktwits
Exposures COVID-19
These S&P500 stocks are moving in today's pre-market session
Get insights into the top gainers and losers in the S&P500 index of Thursday's pre-market session. 
Via Chartmill
Moderna (NASDAQ:MRNA) Misses Q1 Revenue Estimates
Biotechnology company Moderna (NASDAQ:MRNA) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The company’s full-year revenue guidance of $2... 
Via StockStory
Exposures COVID-19
Moderna Misses Sales Forecasts, But Maintains Full-Year Outlook
The company is well known for its Covid vaccine. But sales came in below expectations. 
Via Investor's Business Daily
Topics Earnings Government
Exposures COVID-19 Financial Political
Moderna (MRNA) Reports Earnings Tomorrow: What To Expect
Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence World Trade
Exposures Artificial Intelligence Tariff
Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline
The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine has created uncertainty across the vaccine industry, potentially affecting... 
Via Benzinga
Topics Government
Exposures COVID-19 Political Product Safety
Down 36%, Is Moderna a Buy on the Dip?
Via The Motley Fool
Exposures COVID-19 Product Safety
Market Sell-Off: 2 Stocks Down 17% and 36% This Year to Buy and Hold
Via The Motley Fool
Exposures COVID-19
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
3 Healthcare Stocks Facing Headwinds
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
These S&P500 stocks are moving in today's session
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Monday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Discover which S&P500 stocks are making waves on Monday.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday. 
Via Chartmill
Wall Street Sinks, Dollar Slides As Trump Ramps Up Fed Attacks: What's Driving Markets Monday?
Stocks in the U.S. were trading sharply lower by midday Monday, while gold and Bitcoin (CRYPTO: BTC) surged in tandem, as a renewed political storm surrounding Federal Reserve independence shook... 
Via Benzinga
Topics Economy Government
Exposures Interest Rates Political
Where Will Moderna Be in 5 Years?
Via The Motley Fool
Exposures COVID-19
5 Stocks to Buy the Dip, According to AI
“Buy the dip” strategies are hard to get right, but they can yield phenomenal results. Now, TradeSmith believes they’ve found a way to help longer-term investors find attractive entry points into great... 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years
CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older populations. 
Via Benzinga
Bloom Energy, Rogers, 3D Systems, Moderna, and EchoStar Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after Federal Reserve Chair Jerome Powell signaled a cautious stance on future monetary policy decisions during a speech in Chicago, emphasizing that... 
Via StockStory
Topics Economy Government World Trade
Exposures Economy Interest Rates Political
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Uncover the latest developments among S&P500 stocks in today's session.
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday. 
Via Chartmill
Which S&P500 stocks are moving on Tuesday?
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Tuesday as we examine the latest happenings in today's session. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.